BR112022004776A2 - Anticorpos anti-fator de células-tronco e métodos para uso dos mesmos - Google Patents
Anticorpos anti-fator de células-tronco e métodos para uso dos mesmosInfo
- Publication number
- BR112022004776A2 BR112022004776A2 BR112022004776A BR112022004776A BR112022004776A2 BR 112022004776 A2 BR112022004776 A2 BR 112022004776A2 BR 112022004776 A BR112022004776 A BR 112022004776A BR 112022004776 A BR112022004776 A BR 112022004776A BR 112022004776 A2 BR112022004776 A2 BR 112022004776A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- antibodies
- stem cell
- cell factor
- factor antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900927P | 2019-09-16 | 2019-09-16 | |
| PCT/US2020/050973 WO2021055408A1 (en) | 2019-09-16 | 2020-09-16 | Anti-stem cell factor antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022004776A2 true BR112022004776A2 (pt) | 2022-06-21 |
Family
ID=74868426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022004776A BR112022004776A2 (pt) | 2019-09-16 | 2020-09-16 | Anticorpos anti-fator de células-tronco e métodos para uso dos mesmos |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20220324957A1 (https=) |
| EP (3) | EP4031569B1 (https=) |
| JP (4) | JP7698635B2 (https=) |
| KR (1) | KR20220079561A (https=) |
| CN (2) | CN118561997A (https=) |
| AR (1) | AR119979A1 (https=) |
| AU (2) | AU2020348295A1 (https=) |
| BR (1) | BR112022004776A2 (https=) |
| CA (2) | CA3154649A1 (https=) |
| CL (1) | CL2022000633A1 (https=) |
| CO (1) | CO2022003661A2 (https=) |
| DK (1) | DK4031569T3 (https=) |
| DO (1) | DOP2022000058A (https=) |
| EC (1) | ECSP22022676A (https=) |
| ES (1) | ES3053942T3 (https=) |
| FI (1) | FI4031569T3 (https=) |
| IL (1) | IL291385A (https=) |
| MX (1) | MX2022003159A (https=) |
| PE (1) | PE20230090A1 (https=) |
| PH (1) | PH12022550647A1 (https=) |
| PL (1) | PL4031569T3 (https=) |
| PT (1) | PT4031569T (https=) |
| SA (1) | SA522431966B1 (https=) |
| TW (2) | TWI875812B (https=) |
| UA (1) | UA129546C2 (https=) |
| UY (1) | UY38883A (https=) |
| WO (2) | WO2021055408A1 (https=) |
| ZA (1) | ZA202203272B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| AU2020348295A1 (en) * | 2019-09-16 | 2022-04-07 | Insmed Incorporated | Anti-stem cell factor antibodies and methods of use thereof |
| KR20250167153A (ko) * | 2023-03-03 | 2025-11-28 | 셀덱스 쎄라퓨틱스, 인크. | 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물 |
| WO2026079764A1 (ko) * | 2024-10-10 | 2026-04-16 | 아주대학교산학협력단 | 마우스 scf를 중화하는 항체 및 이의 용도 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2657113B2 (ja) * | 1989-10-16 | 1997-09-24 | アムジエン・インコーポレーテツド | 幹細胞因子 |
| US7144731B2 (en) * | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US5911988A (en) | 1995-04-28 | 1999-06-15 | Bayer Corporation | Method for treating asthma using SCF antibody |
| JP3583214B2 (ja) | 1995-12-01 | 2004-11-04 | 株式会社ニチレイ | ヒトｓｃｆに対するモノクローナル抗体 |
| US20090087878A9 (en) | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
| US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| PL1691837T3 (pl) | 2003-12-10 | 2012-11-30 | Squibb & Sons Llc | IP-10 przeciwciała i ich zastosowanie |
| US7611707B2 (en) | 2004-04-29 | 2009-11-03 | Otsuka Pharmaceutical Co., Ltd. | Glycoprotein VI antibodies and methods thereof |
| WO2006002064A2 (en) | 2004-06-14 | 2006-01-05 | Aerovance, Inc. | Antibody inhibiting stem cell factor activity and use for treatment of asthma |
| US20080248050A1 (en) | 2006-06-30 | 2008-10-09 | Uchicago Argonne, Llc | Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine |
| US20110189093A1 (en) | 2008-04-14 | 2011-08-04 | Proscan Rx Pharma | Prostate specific membrane antigen antibodies and antigen binding fragments |
| AU2012205718B2 (en) | 2011-01-10 | 2017-07-06 | The Regents Of The University Of Michigan | Stem cell factor inhibitor |
| US20150018408A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
| KR101384360B1 (ko) | 2012-05-04 | 2014-04-14 | 아주대학교산학협력단 | Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| US10927153B1 (en) | 2015-05-20 | 2021-02-23 | University Of South Florida | Synthetic plasmodium antigens, compositions, and uses thereof |
| KR102438650B1 (ko) * | 2015-08-19 | 2022-08-31 | 화이자 인코포레이티드 | 조직 인자 경로 억제제 항체 및 그의 용도 |
| KR20170022409A (ko) | 2015-08-20 | 2017-03-02 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| US11091559B2 (en) * | 2015-08-27 | 2021-08-17 | Celldex Therapeutics, Inc. | Anti-ALK antibodies and methods for use thereof |
| CA3009488A1 (en) | 2015-12-22 | 2017-06-29 | Abbvie Stemcentrx Llc | Novel anti-upk1b antibodies and methods of use |
| PL3523421T3 (pl) | 2016-10-05 | 2025-06-09 | Cellresearch Corporation Pte. Ltd. | Sposób izolowania mezenchymalnych komórek macierzystych z błony owodniowej pępowiny przy użyciu podłoża do hodowli komórkowej |
| WO2019066093A1 (ko) | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| WO2019088658A1 (ko) | 2017-10-31 | 2019-05-09 | 주식회사 컴워스파마 | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 |
| KR102131898B1 (ko) | 2017-10-31 | 2020-07-08 | 주식회사 노벨티노빌리티 | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 |
| CA3117098A1 (en) | 2018-10-19 | 2020-04-23 | The General Hospital Corporation | Compositions and methods for treatment of liver disease |
| AU2020348295A1 (en) | 2019-09-16 | 2022-04-07 | Insmed Incorporated | Anti-stem cell factor antibodies and methods of use thereof |
| US20240182556A1 (en) | 2021-03-17 | 2024-06-06 | Opsidio, LLC | Stem cell factor antibodies and methods of use thereof |
-
2020
- 2020-09-16 AU AU2020348295A patent/AU2020348295A1/en active Pending
- 2020-09-16 EP EP20866530.7A patent/EP4031569B1/en active Active
- 2020-09-16 WO PCT/US2020/050973 patent/WO2021055408A1/en not_active Ceased
- 2020-09-16 PE PE2022000419A patent/PE20230090A1/es unknown
- 2020-09-16 MX MX2022003159A patent/MX2022003159A/es unknown
- 2020-09-16 US US17/640,544 patent/US20220324957A1/en active Pending
- 2020-09-16 BR BR112022004776A patent/BR112022004776A2/pt unknown
- 2020-09-16 US US17/022,465 patent/US11939373B2/en active Active
- 2020-09-16 DK DK20866530.7T patent/DK4031569T3/da active
- 2020-09-16 JP JP2022517136A patent/JP7698635B2/ja active Active
- 2020-09-16 UA UAA202201048A patent/UA129546C2/uk unknown
- 2020-09-16 US US17/640,538 patent/US20220340655A1/en not_active Abandoned
- 2020-09-16 EP EP20865210.7A patent/EP4031176A4/en active Pending
- 2020-09-16 FI FIEP20866530.7T patent/FI4031569T3/fi active
- 2020-09-16 CN CN202410508865.2A patent/CN118561997A/zh active Pending
- 2020-09-16 TW TW109131936A patent/TWI875812B/zh active
- 2020-09-16 EP EP25193246.3A patent/EP4650367A3/en active Pending
- 2020-09-16 CA CA3154649A patent/CA3154649A1/en active Pending
- 2020-09-16 PT PT208665307T patent/PT4031569T/pt unknown
- 2020-09-16 WO PCT/US2020/050974 patent/WO2021055409A1/en not_active Ceased
- 2020-09-16 CN CN202080078693.XA patent/CN114729036B/zh active Active
- 2020-09-16 UY UY0001038883A patent/UY38883A/es active IP Right Grant
- 2020-09-16 PH PH1/2022/550647A patent/PH12022550647A1/en unknown
- 2020-09-16 CA CA3154648A patent/CA3154648A1/en active Pending
- 2020-09-16 AR ARP200102566A patent/AR119979A1/es unknown
- 2020-09-16 AU AU2020351138A patent/AU2020351138A1/en active Pending
- 2020-09-16 ES ES20866530T patent/ES3053942T3/es active Active
- 2020-09-16 PL PL20866530.7T patent/PL4031569T3/pl unknown
- 2020-09-16 TW TW114107177A patent/TW202523696A/zh unknown
- 2020-09-16 JP JP2022517173A patent/JP7717687B2/ja active Active
- 2020-09-16 KR KR1020227012536A patent/KR20220079561A/ko active Pending
-
2022
- 2022-03-15 DO DO2022000058A patent/DOP2022000058A/es unknown
- 2022-03-15 CL CL2022000633A patent/CL2022000633A1/es unknown
- 2022-03-15 IL IL291385A patent/IL291385A/en unknown
- 2022-03-16 SA SA522431966A patent/SA522431966B1/ar unknown
- 2022-03-18 ZA ZA2022/03272A patent/ZA202203272B/en unknown
- 2022-03-24 EC ECSENADI202222676A patent/ECSP22022676A/es unknown
- 2022-03-28 CO CONC2022/0003661A patent/CO2022003661A2/es unknown
- 2022-09-06 US US17/929,976 patent/US20230019680A1/en not_active Abandoned
-
2023
- 2023-11-02 US US18/500,622 patent/US12410246B2/en active Active
-
2025
- 2025-06-13 JP JP2025099435A patent/JP2025125563A/ja active Pending
- 2025-07-23 JP JP2025123268A patent/JP2025165991A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004776A2 (pt) | Anticorpos anti-fator de células-tronco e métodos para uso dos mesmos | |
| BR112018000769A2 (pt) | anticorpos específicos para tau hiperfosforilada e métodos para uso dos mesmos | |
| BR112022002837A2 (pt) | Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo | |
| BR112021019135A2 (pt) | Anticorpo anticlaudina 18.2 e aplicação do mesmo | |
| BR112019018685A8 (pt) | Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo | |
| BR112019000436A2 (pt) | anticorpos anti-pd-1, método de produção e método de uso dos mesmos | |
| HK1255039A1 (zh) | 对pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 | |
| BR112013021350A2 (pt) | anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes | |
| NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| CO2021008204A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso | |
| BR112022024262A2 (pt) | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april | |
| EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
| BR112021021281A2 (pt) | Anticorpo monoclonal que se liga especificamente ao gitr | |
| WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
| MX2023009882A (es) | Anticuerpos anti-muc1-c y estructuras car-t. | |
| BR112022005678A2 (pt) | Métodos e composições para o tratamento da retinopatia diabética | |
| BR112016018116A2 (pt) | anticorpo e sequências específicos para e. coli, preparação farmacêutica ou para diagnóstico compreendendo os mesmos, uso do anticorpo para tratar infecção por e. coli e diagnosticar a doença, ácido nucleico que codifica o anticorpo, um cassete de expressão, plasmídeo ou célula hospedeira compreendendo o mesmo, e método de produção | |
| CL2023002968A1 (es) | Anticuerpos anti-cd19 y estructuras car-t | |
| IL286306A (en) | Manufacturing methods for producing anti-tnf antibody compositions | |
| BR112017027702A2 (pt) | anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2) | |
| BR112022026533A2 (pt) | Anticorpo anti-fxi/fxia, fragmento de ligação do mesmo, e antígenos e uso farmacêutico do mesmo | |
| BR112023005980A2 (pt) | Anticorpos cd1a e seus usos | |
| CL2025002201A1 (es) | Métodos de tratamiento de trastornos neurológicos con anticuerpos anti-abeta | |
| CA3046446A1 (en) | Therapies for treating inflammatory disorders | |
| ECSP19018367A (es) | Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 |